Abstract:Insulin-degrading enzyme (IDE) is involved in the clearance of insulin and amyloid β. This is necessary to maintain proper blood sugar levels and to prevent accumulation of amyloid β in the brain. The crystal structure of IDE in complex with four substrates has now been determined, revealing the molecular basis for substrate recognition. This should aid the design of IDE-based drugs for Alzheimer's disease and type II diabetes. The crystal structure of insulin-degrading enzyme (IDE) in complex with four substrates is presented, revealing the molecular basis for substrate recognition by IDE. Insulin-degrading enzyme (IDE), a Zn2+-metalloprotease, is involved in the clearance of insulin and amyloid-β (refs 1–3). Loss-of-function mutations of IDE in rodents cause glucose intolerance and cerebral accumulation of amyloid-β, whereas enhanced IDE activity effectively reduces brain amyloid-β (refs 4–7). Here we report structures of human IDE in complex with four substrates (insulin B chain, amyloid-β peptide (1–40), amylin and glucagon). The amino- and carboxy-terminal domains of IDE (IDE-N and IDE-C, respectively) form an enclosed cage just large enough to encapsulate insulin. Extensive contacts between IDE-N and IDE-C keep the degradation chamber of IDE inaccessible to substrates. Repositioning of the IDE domains enables substrate access to the catalytic cavity. IDE uses size and charge distribution of the substrate-binding cavity selectively to entrap structurally diverse polypeptides. The enclosed substrate undergoes conformational changes to form β-sheets with two discrete regions of IDE for its degradation. Consistent with this model, mutations disrupting the contacts between IDE-N and IDE-C increase IDE catalytic activity 40-fold. The molecular basis for substrate recognition and allosteric regulation of IDE could aid in designing IDE-based therapies to control cerebral amyloid-β and blood sugar concentrations1,8,9.

Identification of Indole-Based Activators of Insulin Degrading Enzyme.

Structure-activity Relationships of Imidazole-Derived 2-[N-carbamoylmethyl-alkylamino]acetic Acids, Dual Binders of Human Insulin-Degrading Enzyme.

Structures of Human Insulin-Degrading Enzyme Reveal a New Substrate Recognition Mechanism

Insulin‐degrading enzyme: an ally against metabolic and neurodegenerative diseases

Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones

Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer’s disease: possible mechanisms of IDE in T2D and AD

Ensemble cryoEM elucidates the mechanism of insulin capture and degradation by human insulin degrading enzyme

Structure of Substrate-free Human Insulin-degrading Enzyme (IDE) and Biophysical Analysis of ATP-induced Conformational Switch of IDE

Inhibition of Insulin Degrading Enzyme to Control Diabetes Mellitus and its Applications on some Other Chronic Disease: a Critical Review

Targeting Insulin Signaling for the Treatment of Alzheimer's Disease.

Targeting Insulin-Degrading Enzyme in Insulin Clearance

Characteristics of Insulin-degrading Enzyme in Alzheimer's Disease: A Meta-Analysis.

Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease.

Degradation of Alzheimer’s Amyloid-β by a Catalytically Inactive Insulin-Degrading Enzyme

Insights into Non-Proteolytic Inhibitory Mechanisms of Polymorphic Early-Stage Amyloid β Oligomers by Insulin Degrading Enzyme

Stabilized Β-Hairpin Peptide Inhibits Insulin Degrading Enzyme.

The core sequence of PIF competes for insulin/amyloid β in insulin degrading enzyme: potential treatment for Alzheimer's disease

Insulin Signaling in Sporadic Alzheimer's Disease.

Identification of Electrostatic Hotspots at the Binding Interface of Amylin and InsulinDegrading Enzyme: A Structural and Biophysical Investigation

Insulin-degrading enzyme regulates insulin-directed cellular autoimmunity in murine type 1 diabetes

PPARgamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons.